HCell News
“The news of HCell’s ambitions is to be applauded, as the notion of helping children to avoid having to go through the worry associated with alopecia areata is something very dear to many hair loss specialists’ hearts.” –Belgravia Centre, London, England.
|
June 26, 2018
prweb.com |
HCell Inc. Appoints New Key Members to Board of Directors
HCell Inc. is pleased to announce the addition of two new members to the Board of Directors: Robert P. Ryan Ph.D. and Marlene Haffner, MD, MPH
Austin, Texas – June 26, 2018 – HCell Inc. (HCell) announced today that Robert P. Ryan Ph.D. and Marlene Haffner, MD, MPH have been appointed to its Board of Directors. HCell is a biotechnology company based in Austin, Texas focusing on treatment solutions for Alopecia Areata in the Pediatric Population. |
|
January 30, 2018
folliclethought.com |
HCell Exclusive: Before and After Photos
Follicle Thought – Hair Growth Treatment News – January 30, 2018 Last week I had the opportunity to join a video conference with the HCell team to discuss their therapy aimed at multiple forms of alopecia. The HCell company emerged on the internet around mid January 2018 through the announcement of their Orphan Drug Designation from the FDA to treat pediatric alopecia areata.... |
|
January 15, 2018
prweb.com |
HCell Granted Orphan Drug Designation from
the U.S. FDA for HC017AA Alopecia Areata in the Pediatric Population HC017AA is the first Orphan Drug Designation (ODD) Granted for Alopecia Areata in the pediatric patients by the FDA
Austin, Texas – January 15, 2018 – HCell Inc. (HCell), a biotechnology company based in Austin, Texas, focusing on Alopecia Areata in the Pediatric Population, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HC017AA for the treatment of pediatric patients with Alopecia Areata, a devastating hair loss disease. |
|
January 15, 2018
obio.ca |
OBIO Pre-CAAP Company: HCell Granted Orphan Drug Designation by FDA for Alopecia Areata in Pedatric Population
“The granting of Orphan Drug Designation by the U.S. FDA is a significant milestone for HCell in the HC017AA development program. We are working diligently to prepare for the clinical study for this significant, yet unmet, medical need for Alopecia Areata in pediatric patients.”
|